Skip to main content

Spiriva Respimat FDA Approval History

FDA Approved: Yes (First approved September 24, 2014)
Brand name: Spiriva Respimat
Generic name: tiotropium bromide
Dosage form: Inhalation Spray
Company: Boehringer Ingelheim Pharmaceuticals, Inc.
Treatment for: Asthma, Maintenance, COPD, Maintenance

Spiriva Respimat (tiotropium bromide) is a long-acting muscarinic antagonist (LAMA) indicated for the long-term, maintenance treatment of chronic obstructive pulmonary disease (COPD) and asthma.

Development timeline for Spiriva Respimat

DateArticle
Feb 16, 2017Approval FDA Expands Approval of Spiriva Respimat (tiotropium bromide) Inhalation Spray for Maintenance Treatment of Asthma in Children
Sep 16, 2015Approval FDA Approves Spiriva Respimat (tiotropium) for Maintenance Treatment of Asthma in Adults and Adolescents
Sep 25, 2014Approval FDA Approves Spiriva Respimat (tiotropium) for the Maintenance Treatment of COPD

See also

Spiriva Respimat (tiotropium bromide) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer